PDEX — Pro-Dex, Inc.

Pro-Dex, Inc. (NASDAQ: PDEX) — deep-value analysis

Date: August 24, 2026 · Reference price: … · Market cap: … (3,196,611 shares at 03/31/2026) Fiscal year: ends June 30 · Latest available filing: 10-Q for Q3 FY2026 (03/31/2026), filed 04/30/2026 Primary sources: 10-K FY2021–FY2025, 10-Q Q1/Q2/Q3 FY2026, DEF 14A 10/07/2025, 8-K 12/18/2025 / 02/12/2026 / 03/23/2026 (SEC EDGAR, CIK 0000788920); data pack data-pack-PDEX-20260824.md; research brief research-PDEX-20260824.md.

Executive summary

Pro-Dex designs and manufactures autoclavable, motorized surgical handpieces (drivers and shavers) for three orthopedic niches — large orthopedics, craniomaxillofacial (CMF) and thoracic — almost entirely as a developer-manufacturer for medical OEMs that put their own brand on the product. The company has 181 employees (06/30/2025), two plants in Irvine and Costa Mesa, an assembly facility in Tustin, and, since February 2026, a second machining shop (APM, acquired for …). A single customer generated 79% of the first nine months of FY2026 sales (… of …) and 75% of receivables. That customer extended its contract through December 2028, with minimum volumes for 2026 and 2027 — the source of the visibility the market pays for.

Operationally, the business is doing well and is hard to dispute. Revenue grew from … (FY2021) to an estimated ~… for FY2026, a 15.2% CAGR. Operating margin rose from 11.9% to 16.6% (9 months FY2026). Shares outstanding fell 12.3% over four years and three quarters, and cumulative buybacks since 2013 — 1,580,919 shares for …, i.e. …/share on average — are, at today’s price, one of the best capital allocations I’ve seen from an issuer this size. Insiders hold 45.9% as a group (proxy 09/23/2025), the CEO was paid … total in FY2025 at a … market-cap company, and sell-side coverage is practically zero.

And yet my thesis is negative at the current price, for a reason that doesn’t appear in the income statement: this business’s profit doesn’t convert into cash. Between FY2021 and Q3 FY2026 (4 years and 9 months), Pro-Dex reported … of cumulative net profit, but generated … of cumulative operating cash flow and, after … of investment (excluding the Franklin building bought for … in FY2021), … of cumulative free cash flow — … a year on average. The reason is structural, not conjunctural: base working capital (receivables + inventory − payables − accrued liabilities) sits at 43.2% of revenue and has stayed between 39% and 46% in each of the last five years. Every new revenue dollar requires 43 cents of working capital before producing anything for the shareholder. On top of that, of the … of cumulative net profit, … (pre-tax) is gains from the portfolio of publicly traded stocks the company manages with excess cash and with borrowed funds — including the … in FY2026 from selling the Monogram stake to Zimmer Biomet.

The figure I carry into the valuation, explicitly stated below, is … of normalized owner earnings (…/share). That puts the stock at 32x normalized free flow and 20.2x trailing EV/EBIT, versus its own five-year median of 12.4x. Triangulating five models gives a margin-of-safety range from … (bear) to … (bull, the most generous defensible case: zero working-capital investment, capex at the recent minimum of … thousand, 10% growth for five years), with a median of …. The Monte Carlo simulation across 20,000 scenarios gives a median intrinsic value of … and a 0.3% probability the stock is undervalued. Not even the most optimistic defensible scenario reaches the market price.

Verdict: AVOID at … Not a bad company — a good company at a price that assumes the cash-conversion problem disappears and that the single-customer relationship extends beyond 2028. The zone where the business becomes interesting is …–38 (the upper half of the triangulation range plus the CVR optionality). An investor already holding the position has a legitimate argument to keep it for the Monogram/Zimmer optionality and the quality of the capital allocator; a new buyer today pays the full value of that optionality and then some.